INTRODUCTION: Current research indicates that chronic peripheral neuropathic pain includes a role for glia and the actions of proinflammatory factors. This review briefly discusses the glial and cytokine responses that occur following peripheral nerve damage in support of utilizing anti-inflammatory cytokine interleukin-10 (IL-10) therapy to suppress chronic peripheral neuropathic pain. SPINAL NONVIRAL INTERLEUKIN-10 GENE THERAPY: IL-10 is one of the most powerful endogenous counter-regulators of proinflammatory cytokine function that acts in the nervous system. Subarachnoid (intrathecal) spinal injection of the gene encoding IL-10 delivered by nonviral vectors has several advantages over virally mediated gene transfer methods and leads to profound pain relief in several animal models. NONVIRAL GENE DELIVERY: Lastly, data are reviewed that nonviral deoxyribonucleic acid (DNA) encapsulated by a biologically safe copolymer, poly(lactic-co-glycolic) acid (PLGA), thought to protect DNA, leads to significantly improved therapeutic gene transfer in animal models, which additionally and significantly extends pain relief. CONCLUSIONS: The impact of these early studies exploring anti-inflammatory genes emphasizes the exceptional therapeutic potential of new biocompatible intrathecal nonviral gene delivery approaches such as PLGA microparticles. Ultimately, ongoing expression of therapeutic genes is a viable option to treat chronic neuropathic pain in the clinic.
INTRODUCTION: Current research indicates that chronic peripheral neuropathic pain includes a role for glia and the actions of proinflammatory factors. This review briefly discusses the glial and cytokine responses that occur following peripheral nerve damage in support of utilizing anti-inflammatory cytokine interleukin-10 (IL-10) therapy to suppress chronic peripheral neuropathic pain. SPINAL NONVIRAL INTERLEUKIN-10 GENE THERAPY: IL-10 is one of the most powerful endogenous counter-regulators of proinflammatory cytokine function that acts in the nervous system. Subarachnoid (intrathecal) spinal injection of the gene encoding IL-10 delivered by nonviral vectors has several advantages over virally mediated gene transfer methods and leads to profound pain relief in several animal models. NONVIRAL GENE DELIVERY: Lastly, data are reviewed that nonviral deoxyribonucleic acid (DNA) encapsulated by a biologically safe copolymer, poly(lactic-co-glycolic) acid (PLGA), thought to protect DNA, leads to significantly improved therapeutic gene transfer in animal models, which additionally and significantly extends pain relief. CONCLUSIONS: The impact of these early studies exploring anti-inflammatory genes emphasizes the exceptional therapeutic potential of new biocompatible intrathecal nonviral gene delivery approaches such as PLGA microparticles. Ultimately, ongoing expression of therapeutic genes is a viable option to treat chronic neuropathic pain in the clinic.
Authors: Erin D Milligan; Evan M Sloane; Stephen J Langer; Travis S Hughes; Brian M Jekich; Matthew G Frank; John H Mahoney; Lindsay H Levkoff; Steven F Maier; Pedro E Cruz; Terence R Flotte; Kirk W Johnson; Melissa M Mahoney; Raymond A Chavez; Leslie A Leinwand; Linda R Watkins Journal: Pain Date: 2006-09-01 Impact factor: 6.961
Authors: Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam Journal: Brain Behav Immun Date: 2008-09-20 Impact factor: 7.217
Authors: Karen Krukowski; Jiacheng Ma; Olga Golonzhka; Geoffroy O Laumet; Tanuja Gutti; John H van Duzer; Ralph Mazitschek; Matthew B Jarpe; Cobi J Heijnen; Annemieke Kavelaars Journal: Pain Date: 2017-06 Impact factor: 6.961
Authors: J Pleticha; S A Malkmus; L F Heilmann; S L Veesart; R Rezek; Q Xu; T L Yaksh; A S Beutler Journal: Gene Ther Date: 2014-10-30 Impact factor: 5.250
Authors: Arden G Vanderwall; Shahani Noor; Melody S Sun; Jacob E Sanchez; Xuexian O Yang; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan Journal: Brain Behav Immun Date: 2017-11-04 Impact factor: 7.217
Authors: Ellen C Dengler; Juewen Liu; Audra Kerwin; Sergio Torres; Clara M Olcott; Brandi N Bowman; Leisha Armijo; Katherine Gentry; Jenny Wilkerson; James Wallace; Xingmao Jiang; Eric C Carnes; C Jeffrey Brinker; Erin D Milligan Journal: J Control Release Date: 2013-03-18 Impact factor: 9.776